Investigation Report on China Glimepiride Market, 2010-2019
Description
According to the statistics of International Diabetes Federation (IDF), in 2013, the prevalence of diabetes among adults aged from 20 to 79 was 8.3% and the number of diabetes patients has reached 382 million in the world, 80% of which come from middle income and low income countries and the figure demonstrates a fast rising trend. It is estimated that by 2035, there will be nearly 592 million people suffering from diabetes in the whole world. The number of diabetes patients in China was estimated to be 98.4 million in 2013, ranking first in the world, followed by India (65.1 million), USA (24.4 million), Brazil (11.9 million) and Russia (10.9 million). IDF estimates that by 2035, the number of diabetes patients in China will reach 143 million, still ranking first in the world while that in America will reach 29.7 million. The fast growth of diabetes in China and other developing countries has put a heavy burden on their social and economic development.
Sulfonylurea has developed into an important part of oral antidiabetic drug ever since its first generation came into the market in 1956. As an insulin secretagogue, sulfonylurea directly acts on sulfonylurea receptor on the cell membrane of pancreatic beta cells, stimulates the release of insulin and enhances postprandial elevated blood sugar’s excitation upon insulin release. Currently, glimepiride is the best-selling product of sulfonylurea in the Chinese market.
First developed and marketed by Dr. Willmar Schwabe Gmbh Co. KG under the trade name of Amaryl in 1995, glimepiride has been approved by FDA as an oral drug that can be used alone or together with insulin. Ever since Aventis introduced glimepiride into China under the trade name of Amaryl in 2001, about 30 enterprises have got the approval to produce it.
Glimepiride can also sensitize beta cells to insulin, ameliorate insulin resistance and it works best outside prancreas. By increasing glucose transporter (GLUT1 and GLUT2), glimepiride can recover glucose absorption so as to maintain the normal level of blood sugar. Characterized by small dose, few side effects, wide application and low rate of hypoglycemia, glimepiride can treat insulin secretion deficiency, recover glucose absorption and relieve hyperinsulinemia.
According to CRI’s market survey, in 2014, Hangzhou Sanofi-Synthelabo Minsheng Pharmaceutical Co., Ltd took up a market share of about 86% for sales value and Sanofi occupied nearly 90% of the glimepiride market in China if Aventis (Italy)’s 3.8% is counted too. The rest market share were occupied by such companies like Wanbang Biopharmaceuticals, Zhongnuo Pharma and Tianan Pharmaceutical. The sales value of glimepiride in sample hospitals was CNY 224 million in 2014 and CAGR reached 30.7% during the period of 2005-2014.
The market size of glimepiride is expected to keep growing in the next few years in China.
Readers can get at least the following information through this report:
According to the statistics of International Diabetes Federation (IDF), in 2013, the prevalence of diabetes among adults aged from 20 to 79 was 8.3% and the number of diabetes patients has reached 382 million in the world, 80% of which come from middle income and low income countries and the figure demonstrates a fast rising trend. It is estimated that by 2035, there will be nearly 592 million people suffering from diabetes in the whole world. The number of diabetes patients in China was estimated to be 98.4 million in 2013, ranking first in the world, followed by India (65.1 million), USA (24.4 million), Brazil (11.9 million) and Russia (10.9 million). IDF estimates that by 2035, the number of diabetes patients in China will reach 143 million, still ranking first in the world while that in America will reach 29.7 million. The fast growth of diabetes in China and other developing countries has put a heavy burden on their social and economic development.
Sulfonylurea has developed into an important part of oral antidiabetic drug ever since its first generation came into the market in 1956. As an insulin secretagogue, sulfonylurea directly acts on sulfonylurea receptor on the cell membrane of pancreatic beta cells, stimulates the release of insulin and enhances postprandial elevated blood sugar’s excitation upon insulin release. Currently, glimepiride is the best-selling product of sulfonylurea in the Chinese market.
First developed and marketed by Dr. Willmar Schwabe Gmbh Co. KG under the trade name of Amaryl in 1995, glimepiride has been approved by FDA as an oral drug that can be used alone or together with insulin. Ever since Aventis introduced glimepiride into China under the trade name of Amaryl in 2001, about 30 enterprises have got the approval to produce it.
Glimepiride can also sensitize beta cells to insulin, ameliorate insulin resistance and it works best outside prancreas. By increasing glucose transporter (GLUT1 and GLUT2), glimepiride can recover glucose absorption so as to maintain the normal level of blood sugar. Characterized by small dose, few side effects, wide application and low rate of hypoglycemia, glimepiride can treat insulin secretion deficiency, recover glucose absorption and relieve hyperinsulinemia.
According to CRI’s market survey, in 2014, Hangzhou Sanofi-Synthelabo Minsheng Pharmaceutical Co., Ltd took up a market share of about 86% for sales value and Sanofi occupied nearly 90% of the glimepiride market in China if Aventis (Italy)’s 3.8% is counted too. The rest market share were occupied by such companies like Wanbang Biopharmaceuticals, Zhongnuo Pharma and Tianan Pharmaceutical. The sales value of glimepiride in sample hospitals was CNY 224 million in 2014 and CAGR reached 30.7% during the period of 2005-2014.
The market size of glimepiride is expected to keep growing in the next few years in China.
Readers can get at least the following information through this report:
- market size of glimepiride in China
- major manufacturers of glimepiride for Chinese market and their market share
- retail price of glimepiride in Chinese market
- market outlook of glimepiride in China
- manufacturers of anti-diabetic drugs
- investors/ research institutions interested in Chinese medicine market
- any interest in the medicine market, please contact CRI for customized survey service
1 RELATED CONCEPTS OF GLIMEPIRIDE
1.1 Indication
1.2 Sales Status in Global Market
2 MARKET PROFILE OF GLIMEPIRIDE IN CHINA
2.1 Patent Status
2.2 Major Manufacturers
2.3 Market Size
3 SURVEY ON SALES STATUS OF GLIMEPIRIDE IN CHINA, 2010-2014
3.1 Sales Value
3.1.1 Overall Sales Value
3.1.2 Sales Value by Regions
3.2 Sales Volume
3.2.1 Overall Sales Volume
3.2.2 Sales Volume by Regions
4 SURVEY ON MARKET SHARE OF MAJOR MANUFACTURERS OF GLIMEPIRIDE IN CHINA, 2010-2014
4.1 Market Share by Sales Value
4.2 Market Share by Sales Volume
5 SURVEY ON DOSAGE FORMS OF GLIMEPIRIDE IN CHINA, 2010-2014
5.1 Share of Different Dosage Forms by Sales Value
5.2 Share of Different Dosage Forms by Sales Volume
6 REFERENCE PRICE OF GLIMEPIRIDE IN CHINESE HOSPITALS IN 2014
6.1 Hangzhou Sanofi-Synthelabo Minsheng Pharmaceutical Co., Ltd (Trade Name: Amaryl)
6.2 Aventis(Italy)
6.3 Wanbang Biopharmaceuticals
6.4 Zhongnuo Pharma
6.5 Tianan Pharmaceutical
6.6 Guangzhou Hairui Pharmaceutical Co., Ltd
6.7 Sichuan Pudu Pharmaceutical Plant
7 MAJOR MANUFACTURERS OF GLIMEPIRIDE IN CHINESE MARKET, 2010-2014
7.1 Hangzhou Sanofi-Synthelabo Minsheng Pharmaceutical Co., Ltd
7.2 Aventis(Italy)
7.3 Wanbang Biopharmaceuticals
7.4 Zhongnuo Pharma
7.5 Tianan Pharmaceutical
7.6 Guangzhou Hairui Pharmaceutical Co., Ltd
8 MARKET OUTLOOK OF GLIMEPIRIDE IN CHINA, 2015-2019
8.1 Forecast of Market Size
8.2 Forecast of Competitive Landscape
TABLE OF SELECTED CHARTS
Chart Patent Registration Information of Glimepiride in China
Chart Approval Status of Glimepiride in China
Chart Sales Status of Glimepiride in China, 2010-2014
Chart Sales Value of Glimepiride in China, 2010-2014
Chart Sales Value of Glimepiride by Regions in China, 2010-2014
Chart Sales Value of Glimepiride Tablets in China, 2010-2014
Chart Sales Value of Glimepiride Capsules in China, 2010-2014
Chart Market Share of Major Manufacturers of Glimepiride for Sales Value in China, 2010-2014
Chart Sales Value and Market Share of Glimepiride Made by Hangzhou Sanofi-Synthelabo Minsheng Pharmaceutical Co., Ltd, 2010-2014
Chart Sales Value and Market Share of Glimepiride Made by Aventis (Italy), 2010-2014
Chart Sales Value and Market Share of Glimepiride Made by Wanbang Biopharmaceuticals, 2010-2014
Chart Sales Value and Market Share of Glimepiride Made by Zhongnuo Pharma, 2010-2014
Chart Price of Glimepiride Made by Hangzhou Sanofi-Synthelabo Minsheng Pharmaceutical Co., Ltd in Some Chinese Cities, 2010-2014
Chart Price of Glimepiride Made by Aventis (Italy) in Some Chinese Cities, 2010-2014
Chart Price of Glimepiride Made by Wanbang Biopharmaceuticals in Some Chinese Cities, 2010-2014
Chart Price of Glimepiride Made by Zhongnuo Pharma in Some Chinese Cities, 2010-2014
1.1 Indication
1.2 Sales Status in Global Market
2 MARKET PROFILE OF GLIMEPIRIDE IN CHINA
2.1 Patent Status
2.2 Major Manufacturers
2.3 Market Size
3 SURVEY ON SALES STATUS OF GLIMEPIRIDE IN CHINA, 2010-2014
3.1 Sales Value
3.1.1 Overall Sales Value
3.1.2 Sales Value by Regions
3.2 Sales Volume
3.2.1 Overall Sales Volume
3.2.2 Sales Volume by Regions
4 SURVEY ON MARKET SHARE OF MAJOR MANUFACTURERS OF GLIMEPIRIDE IN CHINA, 2010-2014
4.1 Market Share by Sales Value
4.2 Market Share by Sales Volume
5 SURVEY ON DOSAGE FORMS OF GLIMEPIRIDE IN CHINA, 2010-2014
5.1 Share of Different Dosage Forms by Sales Value
5.2 Share of Different Dosage Forms by Sales Volume
6 REFERENCE PRICE OF GLIMEPIRIDE IN CHINESE HOSPITALS IN 2014
6.1 Hangzhou Sanofi-Synthelabo Minsheng Pharmaceutical Co., Ltd (Trade Name: Amaryl)
6.2 Aventis(Italy)
6.3 Wanbang Biopharmaceuticals
6.4 Zhongnuo Pharma
6.5 Tianan Pharmaceutical
6.6 Guangzhou Hairui Pharmaceutical Co., Ltd
6.7 Sichuan Pudu Pharmaceutical Plant
7 MAJOR MANUFACTURERS OF GLIMEPIRIDE IN CHINESE MARKET, 2010-2014
7.1 Hangzhou Sanofi-Synthelabo Minsheng Pharmaceutical Co., Ltd
7.2 Aventis(Italy)
7.3 Wanbang Biopharmaceuticals
7.4 Zhongnuo Pharma
7.5 Tianan Pharmaceutical
7.6 Guangzhou Hairui Pharmaceutical Co., Ltd
8 MARKET OUTLOOK OF GLIMEPIRIDE IN CHINA, 2015-2019
8.1 Forecast of Market Size
8.2 Forecast of Competitive Landscape
TABLE OF SELECTED CHARTS
Chart Patent Registration Information of Glimepiride in China
Chart Approval Status of Glimepiride in China
Chart Sales Status of Glimepiride in China, 2010-2014
Chart Sales Value of Glimepiride in China, 2010-2014
Chart Sales Value of Glimepiride by Regions in China, 2010-2014
Chart Sales Value of Glimepiride Tablets in China, 2010-2014
Chart Sales Value of Glimepiride Capsules in China, 2010-2014
Chart Market Share of Major Manufacturers of Glimepiride for Sales Value in China, 2010-2014
Chart Sales Value and Market Share of Glimepiride Made by Hangzhou Sanofi-Synthelabo Minsheng Pharmaceutical Co., Ltd, 2010-2014
Chart Sales Value and Market Share of Glimepiride Made by Aventis (Italy), 2010-2014
Chart Sales Value and Market Share of Glimepiride Made by Wanbang Biopharmaceuticals, 2010-2014
Chart Sales Value and Market Share of Glimepiride Made by Zhongnuo Pharma, 2010-2014
Chart Price of Glimepiride Made by Hangzhou Sanofi-Synthelabo Minsheng Pharmaceutical Co., Ltd in Some Chinese Cities, 2010-2014
Chart Price of Glimepiride Made by Aventis (Italy) in Some Chinese Cities, 2010-2014
Chart Price of Glimepiride Made by Wanbang Biopharmaceuticals in Some Chinese Cities, 2010-2014
Chart Price of Glimepiride Made by Zhongnuo Pharma in Some Chinese Cities, 2010-2014
